BERGENBIO ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1504 NOK | -3.59% |
|
-7.96% | -45.90% |
| Sales 2023 | 354K 32.11K 2.68M | Sales 2024 * | - | Capitalization | 588M 53.32M 4.45B |
|---|---|---|---|---|---|
| Net income 2023 | -190M -17.23M -1.44B | Net income 2024 * | -195M -17.69M -1.47B | EV / Sales 2023 | 1,670 x |
| Net cash position 2023 | 156M 14.19M 1.18B | Net Debt 2024 * | 70.86M 6.43M 536M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-2.14
x | P/E ratio 2024 * |
-2.08
x | Employees | 25 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 46.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on BerGenBio ASA
More press releases
| 1 day | -3.59% | ||
| 1 week | -7.96% | ||
| Current month | -22.47% | ||
| 1 month | -16.81% | ||
| 3 months | -47.23% | ||
| 6 months | -22.79% | ||
| Current year | -45.90% |
1 week
0.14
0.17
1 month
0.140.20
Current year
0.140.36
1 year
0.082.02
3 years
0.0829.60
5 years
0.0854.00
10 years
0.0854.80
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Olin
CEO | Chief Executive Officer | 55 | 08/21/08 |
Rune Skeie
DFI | Director of Finance/CFO | 51 | 05/18/05 |
Nigel McCracken
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sally Bennett
BRD | Director/Board Member | 52 | 09/20/09 |
Sveinung Hole
BRD | Director/Board Member | 57 | 01/10/01 |
| Chairman | 63 | 06/22/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.1504 | -3.59% | 87,228,100 |
| 25/24/25 | 0.156 | -5.45% | 28,205,060 |
| 24/24/24 | 0.165 | +5.10% | 14,653,840 |
| 23/24/23 | 0.157 | -0.25% | 16,016,930 |
| 22/24/22 | 0.1574 | -3.67% | 9,529,377 |
Real-time Oslo Bors, April 26, 2024 at 08:15 pm IST
More quotes
Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
Calendar
23/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.1504
NOK
Average target price
0.7667
NOK
Spread / Average Target
+409.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.90% | 53.23M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BGBIO Stock
